10x Genomics has announced it is shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay. The offering gives researchers access to the whole transcriptome across their entire tissue, enabling true unbiased discovery in FFPE samples for the first time.

Izon Science Ltd, the manufacturer of nano-biological separation and characterization tools, announced today the release of two new kits: the qEV Concentration Kit for the isolation and concentration of extracellular vesicles (EVs), and the qEV RNA Extraction Kit, which enables the extraction of RNA from EVs.

Sphere Fluidics and ClexBio have announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.

Foresight Diagnostics has announced the close of its $12.5M Series A financing to commercialize the minimal residual disease (MRD) detection assay.

Autoscribe Informatics releases v6.0 of Matrix Gemini LIMS. V6.0 is a major technological upgrade, that also provides users with an enhanced calculation engine and additional multi language support.

Cmed Technology has announced increased capabilities for encapsia, its advanced enterprise, cloud-based clinical data system, after increased demand for its use in decentralized trials.

MEGIN is pleased to announce the acquisition of a TRIUX™ neo by The Centre For Cognitive Neuroimaging at the Institute for Neuroscience and Psychology at the University of Glasgow. This research facility will continue its role as the only MEG site in Scotland, continuously supporting neuroimaging related research.

ERS Genomics Limited has announced that the Japanese Patent Office (JPO) has rejected arguments filed in opposition to the second Japanese patent. In addition, the JPO has allowed a third CVC patent which covers a chimeric version of the Cas9 protein.

Scientific Products has announced one of the world’s largest simultaneous installations of commercial lyophilizers for use in the production of diagnostic tests. The order, for SP lyophilizers, was made last year in response to the need for an increase in SARS-CoV-2 testing.

Cytel’s biostatisticians have evaluated the difficulties of conducting randomized control trials in low- and middle-income countries, and have revealed the power of new, innovative statistical methods to overcome the most pressing challenges in global health research.